Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by jdstoxon Dec 04, 2017 2:27pm
131 Views
Post# 27086882

RE:RE:RE:RE:Trading Halt

RE:RE:RE:RE:Trading HaltStockwatch's editing of press release captions has been a problem for a long time.

On June 13 Bioasis put out a PR with the caption, "Bioasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders."

Stockwatch edited the caption and released it as, "Bioasis assesses, to continue with Transcend platform."

As if...!!

Implicit in the Stockwatch version, found [url=https://www.stockwatch.com/News/Item.aspx?bid=Z-C:BTI-2479998&symbol=BTI®ion=C]here[/url], is the notion that the assessment was about whether Bioasis was going to advance Transcend or not. As if that question was ever on the table!!

Stockwatch has had a long and troubling record of messing with press releases, including truncating some press releases, which eliminates the "About" sections of PRs. Those "About" sections do change and when Stockwatch cuts off them off, the changes are not seen by readers.

There is a lot of work put into press releases, including their captions. Stockwatch should not be editing them in any way, especially in ways that incorrectly characterize them. Their editing is often contemptuous of junior companies and it's not Stockwatch's place to offer their almost always uninformed opinions about these companies.

jdstox

Bullboard Posts